Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Immunocore (NASDAQ:IMCR) in a research report released on Monday. The firm issued a buy rating and a $48.00 price target on the stock.

A number of other analysts have also commented on IMCR. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Oppenheimer boosted their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunocore in a research note on Tuesday, May 27th. They set a “buy” rating and a $65.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, June 2nd. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.89.

Immunocore Stock Performance

NASDAQ:IMCR opened at $32.59 on Monday. The company has a fifty day moving average of $33.29 and a 200-day moving average of $31.31. The firm has a market capitalization of $1.64 billion, a P/E ratio of -81.48 and a beta of 0.77. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. Immunocore has a twelve month low of $23.15 and a twelve month high of $39.33.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. The company had revenue of $130.65 million during the quarter, compared to analyst estimates of $122.96 million. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. Immunocore’s revenue for the quarter was up 30.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) EPS. As a group, sell-side analysts anticipate that Immunocore will post -0.94 EPS for the current year.

Institutional Trading of Immunocore

Several institutional investors have recently made changes to their positions in IMCR. GF Fund Management CO. LTD. purchased a new position in shares of Immunocore in the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after buying an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Immunocore in the 2nd quarter worth about $42,000. State of Tennessee Department of Treasury purchased a new position in shares of Immunocore in the 2nd quarter worth about $132,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Immunocore in the 1st quarter worth about $225,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.